Novel therapies in breast cancer: what is new from ASCO 2008.
about
Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-AnalysisSurvivin is a novel target of CD44-promoted breast tumor invasionAbundance of a distinct cluster of telomere t-stumps in advanced breast cancer cell line.A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.TNRC9 rs12443621 and FGFR2 rs2981582 polymorphisms and breast cancer risk.ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells.
P2860
Q28547354-D1B44B2D-4717-4E30-86E1-A5420DB2C945Q35168013-65307957-4124-44CB-A865-25A99A5030B6Q36216636-361F7A1E-6C24-4416-88EE-9DC6CEAC61E8Q36480044-E94E8EFC-6F8F-4599-A242-18734AC7A8FAQ36611618-6ECB3645-1B84-4853-9CF2-8CB60386C37CQ37970020-CBCBFB7D-C4AC-4E18-A253-AE0AE6996E08Q43191223-50BE2ADA-4D40-4719-BB96-AB51F7299294
P2860
Novel therapies in breast cancer: what is new from ASCO 2008.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Novel therapies in breast cancer: what is new from ASCO 2008.
@en
type
label
Novel therapies in breast cancer: what is new from ASCO 2008.
@en
prefLabel
Novel therapies in breast cancer: what is new from ASCO 2008.
@en
P2860
P356
P1476
Novel therapies in breast cancer: what is new from ASCO 2008.
@en
P2093
P2860
P2888
P356
10.1186/1756-8722-1-16
P5008
P577
2008-10-01T00:00:00Z
P5875
P6179
1016916214